UnitedHealth Group (NYSE: UNH) has recently faced significant challenges, including a Department of Justice investigation into alleged Medicare fraud, the abrupt resignation of CEO Andrew Witty, and the tragic death of a top executive. These events, coupled with rising medical costs and regulatory pressures, led to a sharp decline in the stock price, dropping nearly 50% over the past month. However, the company's fundamentals remain strong, with a diversified healthcare services portfolio and a history of consistent earnings growth. The return of former CEO Stephen Hemsley, who has demonstrated confidence by purchasing $25 million in shares, suggests a commitment to steering the company back on course.

Analysts maintain a positive long-term outlook for UnitedHealth, citing its resilient business model and potential for earnings recovery by 2026. The stock's current valuation, trading at approximately 10 times forward earnings, presents an attractive entry point for investors with a long-term perspective. While short-term volatility may persist due to ongoing investigations and operational challenges, UnitedHealth's scale, technological assets, and diversified revenue streams position it well for a robust recovery. For investors seeking exposure to the healthcare sector, UNH offers a compelling opportunity as a long-term hold.